<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871490</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003370</org_study_id>
    <nct_id>NCT04871490</nct_id>
  </id_info>
  <brief_title>Improving Detection and Early Action for HPV-positive Oropharynx Cancer</brief_title>
  <acronym>IDEA-HPV</acronym>
  <official_title>Improving Detection and Early Action for HPV-positive Oropharynx Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether a blood test for HPV DNA can improve diagnosis of&#xD;
      HPV-positive oropharynx cancer (HPV-OPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis of HPV-OPC is often delayed. In this study, individuals with signs or symptoms&#xD;
      potentially related to HPV-OPC, such as unexplained throat pain, tonsil or tongue base&#xD;
      asymmetry, or a neck mass, will have their blood tested for circulating HPV DNA. A positive&#xD;
      test may indicate that their symptoms are caused by HPV-OPC, and their treating physician&#xD;
      will be encouraged to complete all the necessary testing to determine whether this is the&#xD;
      case.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of circulating HPV DNA</measure>
    <time_frame>Test results are returned within 1 week.</time_frame>
    <description>Proportion of participants with circulating HPV DNA detected in their blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive value of circulating HPV DNA</measure>
    <time_frame>Long-term follow-up for up to 2 years</time_frame>
    <description>Proportion of participants with positive circulating HPV DNA for whom HPV-OPC is detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV-OPC awareness</measure>
    <time_frame>At the time of study enrollment</time_frame>
    <description>Awareness of HPV-OPC and other HPV-related malignancies among participants will be assessed by a brief survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on clinical practice</measure>
    <time_frame>Within 2-3 weeks of study enrollment</time_frame>
    <description>The proportion of participants for whom clinicla management by the treating clinician is affected by results of the blood test will be measured by a survey sent to treating clinicials</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HPV Positive Oropharyngeal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All eligible participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test for HPV DNA</intervention_name>
    <description>All participants will have blood tested for HPV DNA.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neck mass present for &gt;2 weeks with no signs/symptoms of infection&#xD;
&#xD;
          -  Neck mass present for &gt;2 weeks with signs/symptoms of infection that did not resolve&#xD;
             with antibiotic therapy&#xD;
&#xD;
          -  Palatine or lingual tonsillar asymmetry on physical exam&#xD;
&#xD;
          -  Palatine or lingual tonsillar asymmetry on imaging, including asymmetric FDG uptake in&#xD;
             palatine or lingual tonsils on PET-CT scans&#xD;
&#xD;
          -  Unexplained throat pain for &gt;2 weeks that did not resolve with antibiotic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known diagnosis of HPV-OPC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eleni Rettig, MD</last_name>
    <phone>617-632-3643</phone>
    <email>emrettig@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Rettig, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Eleni M. Rettig, MD</investigator_full_name>
    <investigator_title>Head &amp; Neck Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

